
Objective To evaluate the efficacy and safety of brepocitinib, an oral, selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with active NIU. Design NEPTUNE was a 52-week, phase 2, multicenter, double-masked, randomized, dose-ranging clinical trial conducted in the United States between November 2022 and July 2024. Participants were randomized 2:1 to receive brepocitinib 45 mg or 15 mg once daily. All participants underwent an accelerated protocol-mandated glucocorticoid taper, with discontinuation of systemic and topical steroids by Week 8. Subjects Adults between the ages of 18 and 74 with active NIU were eligible for enrollment. Intervention and methods Participants received oral brepocitinib 45 mg or 15 mg once daily. The primary efficacy outcome was the proportion of participants experiencing treatment failure (TF) by Week 24, which was compared with a prespecified historical placebo rate of 80%. Additional outcomes included TF through Week 52 and effects on visual acuity, ocular inflammation, and macular edema. Safety was assessed in all participants who received at least one dose of brepocitinib. Results Twenty-six participants (mean age, 42 years; 65% female) were enrolled. By Week 24, TF occurred in 29.4% (95% CI, 10.3–56.0) of participants receiving brepocitinib 45 mg and 44.4% (95% CI, 13.7–78.8) receiving brepocitinib 15 mg, reflecting significant reductions relative to the prespecified historical placebo rate (p < 0.0001 and p = 0.0196, respectively). Through Week 52, only one additional TF event occurred in each treatment group. Improvements in visual acuity, posterior segment inflammation, and macular edema favored brepocitinib 45 mg. Brepocitinib was generally well-tolerated, with no deaths, major adverse cardiovascular events, venous thromboembolic events, or malignancies. Conclusions In this phase 2 randomized trial, brepocitinib was associated with low TF rates and rapid, durable disease control despite an accelerated glucocorticoid taper. Improvements across clinical, angiographic, and structural outcomes favored the 45 mg dose and support further evaluation of TYK2/JAK1 inhibition as a promising glucocorticoid-sparing treatment strategy for NIU.Trial registration ClinicalTrials.gov, NCT05523765
Purpose To evaluate the diagnostic capacity of Melbourne Rapid Fields 24–2 Rapid protocol (MRFr) web–browser perimetry using clinical examination, Humphrey Visual Field Analyzer Swedish Interactive Thresholding Algorithm Standard (HFA–SS), and optical coherence tomography as the reference standards. Design Prospective cross–sectional study. Subjects Eighty–three eyes from 83 glaucoma patients and 52 eyes from 52 non–glaucoma participants were enrolled at Kurashiki Medical Center. Methods Participants underwent HFA–SS 24–2, followed by MRFr. The primary outcome measures included mean deviation (MD), pattern standard deviation (PSD), test false–positive rate, and test duration. Results MRFr returned a significant level of agreement with HFA–SS for MD (Intraclass Correlation Coefficient, ICC = 0.91 {95% Confidence Limit, CL 0.87 to 0.94}) and PSD (ICC = 0.89 {95%CL 0.82 to 0.93}). Bland–Altman analysis for MRFr and HFA–SS found a bias of –0.70 decibels (dB) (Coefficient of Repeatability, CoR = 6.74) for MD and +0.77 dB (CoR = 5.17) for PSD. To evaluate the performance of HFA–SS and MRFr for diagnosing glaucoma, receiver operating characteristic (ROC) curves were analyzed. Although a statistically significant difference in sensitivity of MD was observed at a specificity of 95% (51.8% for HFA–SS, 68.7% for MRFr; p = 0.009), the overall difference in the area under the curve (AUC) of the ROC curves was small, and the ROC curves crossed at certain points. The AUCs for MD were 0.87 ± 0.03 and 0.85 ± 0.03 for MRFr and HFA–SS, respectively. AUCs for PSD were 0.85 ± 0.03 and 0.91 ± 0.03 for MRFr and HFA–SS, respectively. The average test false–positive rate of MRFr was lower than that of HFA–SS (2.0 ± 4.6 vs 2.8 ± 4.0; p = 0.006). MRFr (161 ± 41 s) was significantly faster than HFA–SS (329 ± 67 s) (p < 0.001). Conclusion MRFr provides fast, portable, reliable visual field test for glaucoma diagnosis.
Purpose: To report the surgical outcomes and clinical course after cultivated autologous oral mucosal epithelial transplantation (COMET) using Sakracy® (CynosBio, Inc.), a commercially available autologous oral mucosal epithelial cell sheet cultured on human amniotic membrane (AM) for conjunctival fornix reconstruction in eyes with severe ocular surface disorders after previous AM transplantation (AMT). Observations: This retrospective interventional case series study involved 3 eyes of 3 patients (1 male and 2 females) with severe cicatricial ocular surface disorders; i.e., 2 eyes with clinically diagnosed ocular cicatricial pemphigoid and 1 eye with Stevens–Johnson syndrome. All 3 eyes had previously undergone AMT, after which recurrent symblepharon and/or progressive fornix shortening developed. Symblepharon release and COMET using Sakracy® were subsequently performed for conjunctival fornix reconstruction. In all cases, a deep conjunctival fornix was maintained throughout the 20- to 29-month follow-up, allowing continued therapeutic limbal-rigid contact lens (Suncon Kyoto-CS; Sun Contact Lens Co., Ltd.) wear in 2 eyes. However, 1 eye required additional AMT for partial symblepharon recurrence, and persistent ocular surface keratinization remained in another eye. Conclusion: The findings in this case series suggest that COMET using Sakracy® may represent a useful therapeutic option to maintain a deep conjunctival fornix in eyes with severe cicatricial ocular surface disorders when previous AMT insufficiently maintains fornix reconstruction.
Purpose To assess the global distribution of awareness and screening activities conducted during World Glaucoma Week (WGW) and to identify national-level factors associated with activity frequency. Design Cross-sectional observational study. Subjects Countries and cities reporting WGW activities (2015–2024) on the official WGW website. Methods Activity rates were standardized per 10,000 individuals with glaucoma-related blindness in each country. Pearson’s and Spearman’s correlation analysis was used to examine associations between WGW activity levels and national indicators, including the presence of a glaucoma society, the number of ophthalmologists, Gross Domestic Product (GDP), and Inequality-adjusted Human Development Index (IHDI) Results An average of 548.1 WGW activities were reported annually. Public education (30.9%) and awareness campaigns (30.2%) were the most frequently conducted activities. Manila, Philippines, reported the highest average number of activities per year (35.3), followed by Quito, Ecuador, and Bogotá, Colombia. When adjusted for glaucoma-related blindness, Antigua and Barbuda had the most frequent activities, followed by Barbados and Croatia. Countries with a national glaucoma society reported significantly more activities (median 19.50 [IQR 4.00–54.75] vs. 0.00 [IQR 0.00–2.50]; p < 0.001). Significant correlations were observed between WGW activity levels and population size, IHDI, number of ophthalmologists, and glaucoma blindness prevalence as estimated by the Global Burden of Disease Study. Conclusions Marked global disparities exist in glaucoma awareness efforts. The presence of a national glaucoma society is strongly associated with increased WGW activity levels, underscoring the critical role of organized professional support as a major driver of glaucoma awareness worldwide.
Topic The claim that increasing oral water intake reduces vitreous floaters or restores vitreous integrity is widespread across social media and clinical settings. This narrative review evaluates the biological plausibility of this claim using established vitreous physiology, barrier transport data, floater pathophysiology, and an original quantitative appraisal. A clearly delineated hypothesis regarding seasonal variation in posterior vitreous detachment is also presented. Clinical relevance New or worsening floaters may signal retinal tear, rhegmatogenous retinal detachment, vitreous hemorrhage, endophthalmitis, posterior uveitis, primary vitreoretinal lymphoma, or proliferative diabetic retinopathy. With ophthalmology-related content accumulating billions of views on social media platforms and a substantial proportion containing inaccurate information, the hydration-floater claim has the potential to delay diagnosis of sight-threatening or life-threatening conditions. Methods Narrative critical review of primary literature on vitreous physiology, blood-retinal barrier kinetics, aquaporin-mediated water transport, collagen type II biology, hyaluronic acid biochemistry, vitreous ascorbate physiology, floater pathophysiology, and the epidemiology of seasonal posterior vitreous detachment. Literature searched in PubMed, Scopus, and Embase through June 2026. Original quantitative calculations are explicitly labeled as author-derived estimates throughout. This review does not constitute a systematic review or meta-analysis. Results Vitreous water content (∼4.14 mL per eye; 0.02% of total body water) is maintained by the blood-retinal barrier and aquaporin-4-mediated Müller cell transport, largely independently of oral intake. Author-derived quantitative estimates indicate that the theoretical water influx from systemic oral loading is approximately 1.2% of vitreous volume per eye (0.049 mL / 4.14 mL) under the maximally favorable scenario of completely unrestricted equilibration with no barrier restriction — and substantially less under realistic physiological conditions. Floaters arise from thermodynamically highly favored aggregation of collagen type II fibrils following hyaluronic acid depletion — a process that is effectively irreversible under physiological conditions given the activation energies involved (15–50 kJ/mol); the vitreous becomes progressively more liquid with aging, not less. The largest epidemiological study on water intake and ocular surface disease (n=51,551) found no protective effect against dry eye disease. Increased oral hydration has not been demonstrated to reduce floaters in any published study. As a hypothesis-generating proposal, seasonal variation in posterior vitreous detachment and rhegmatogenous retinal detachment in temperate climates may reflect thermodynamic destabilization of vitreous collagen near its melting transition temperature, rather than dehydration; this mechanism awaits direct experimental validation. Conclusions Increased oral water intake has not been demonstrated to alter vitreous water content, collagen fibril architecture, or floater burden. These processes are regulated by the blood-retinal barrier and membrane transport mechanisms in a manner largely independent of systemic hydration, though direct in vivo measurement under graded oral loading conditions in humans remains an evidence gap. New or worsening floaters require ophthalmological evaluation, not reassurance based on hydration advice.